Liquid pharmaceutical composition

A technology of liquid medicine and composition, applied in the field of treating subjects suffering from the following diseases, capable of solving problems such as gabapentin bitterness

Inactive Publication Date: 2004-06-30
WARNER LAMBERT CO LLC
View PDF32 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Additionally, gabapentin was found to have an extremely bitter taste

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liquid pharmaceutical composition
  • Liquid pharmaceutical composition
  • Liquid pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1a

[0091] Example 1 a Example 2 Example 3 Example 4

[0092] Gabapentin 2.000 5.000 5.000 5.000

[0093] Xylitol 20.000 30.000 30.000 29.940

[0094] Strawberry / Fennel Spice 1.000 -- -- 1.000

[0095] Blackberry / Fennel -- 1.000 1.000 --

[0096] material

[0097] 95% Glycerin 50.000 40.000 30.000 43.790

[0098] 0.1N hydrochloric acid -- 7.720 -- --

[0099] 0.1N sodium hydroxide -- -- 0.770 --

[0100] Pure water 27.000 16.280 33.230 20.27

[0101] pH 6.2 5.5 7.0 6.5

[0102] a Quantity in grams / 100mL

[0103] General process for the preparation of two-component liquid compositions of gabapentin

[0104] Step [A] Powder Blend

[0105] Gabapentin or pregabalin monohydrate (US Patent No. US 4,894,476) is blended with sorbitol.

[0106] Step [B] Syrup Base

[0107] Dissolve the sorbitol solution, glycerin, sugar granules, menthol flavor, artificial fennel flavor, and artificial bilberry flavor in distilled water.

[0108] Step [C] Finished Syrup ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention describes liquid pharmaceutical compositions of GABA analogs having a pH of from about 5.5 to about 7.0 comprising at least one polyol containing 2 to 6 carbon atoms and also discloses comprising a first ingredient and a second ingredient two-component liquid pharmaceutical compositions, wherein the first component comprises a powder mixture containing GABA analogs and a solid polyol, and the second component comprises a liquid base; the present invention also describes the use of these compositions. Methods of making and using therapeutically effective amounts of the pharmaceutical compositions to treat the following disorders: Brain disorders, including epilepsy, fainting episodes, hypokinesia, and intracranial trauma; neurodegenerative disorders; depression; mania and bipolar disorder Disorders; anxiety; panic; inflammation; renal colic; insomnia; gastrointestinal impairment; incontinence; pain, including neuropathic pain, myalgia, bone pain, and migraine.

Description

field of invention [0001] The present invention relates to liquid pharmaceutical compositions comprising gamma-aminobutyric acid (GABA) analogs, methods for their preparation, and methods of using such compositions to treat subjects, including human subjects, suffering from certain brain Illness, including epilepsy, fainting episodes, hypokinesia, and intracranial trauma; neurodegenerative disease; depression; mania and bipolar disorder; anxiety; panic; inflammation; renal colic; insomnia; gastrointestinal impairment; incontinence ; Pain, including neuropathic pain, myalgia, skeletal pain, and migraine. Background of the invention [0002] GABA is an inhibitory amino acid found in the mammalian central nervous system (CNS). It has been reported that dysfunction of GABA neurotransmission in the CNS can produce and even lead to psychosis and neurological diseases, such as epilepsy, schizophrenia, Parkinson's disease, Huntington's disease and hypokinesia (Saletu B. et al., Int...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D207/263A61K9/00A61K9/08A61K31/197A61K31/4015A61K47/10A61P1/04A61P19/00A61P21/00A61P25/04A61P25/06A61P25/08A61P25/20A61P25/22A61P25/24A61P25/28A61P29/00C07D209/54
CPCA61K9/0095A61P1/00A61P1/04A61P13/00A61P19/00A61P21/00A61P25/00A61P25/04A61P25/06A61P25/08A61P25/20A61P25/22A61P25/24A61P25/28A61P29/00A61K9/08
Inventor 尼马·M·库尔卡尼迈克尔·施奈德史蒂文·B·西尔伯林汉斯·R·迈耶-旺内伊纳希德·萨尼-亚雅
Owner WARNER LAMBERT CO LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap